A comparison becomes useful when you can say who was studied, which medicines and regimens were tested, what was measured and when. Start with those details before turning a weight-loss headline into a question about your own treatment. This guide uses one actual head-to-head trial, a worked numbers example and a private study-note sheet to help you prepare for a conversation with your clinician.

Start with the actual research question

SURMOUNT-5 randomized 751 adults with obesity without type 2 diabetes. It compared maximum-tolerated weekly injections of tirzepatide, 10 or 15 mg, with semaglutide, 1.7 or 2.4 mg, for 72 weeks. It was an open-label trial funded by Eli Lilly. The main outcome was percentage change in body weight from the starting measurement to week 72. [1] Those doses describe the experiment; they are not instructions for choosing, changing or converting a prescription.

Randomization means treatment assignment uses chance. Blinding is a different feature that can reduce the influence of knowing the treatment assignment. NIH explains these as separate elements of study design. [3] An open-label comparison can still provide useful randomized evidence; record that feature alongside its population, duration and outcome rather than treating every study design as interchangeable.

Use five questions before comparing results

Original study-reading prompts — check the report, protocol and exact product label
Reading questionWhat to locateNote#
Who took part?Locate the population and important exclusionsPeople[2]
What was tested?Record each product, route and studied regimenProducts[1]
What was measured?Find the outcome definition and measurement timeEndpoint[1]
Which analysis?Check how stopping treatment and missing data were handledAnalysis[2]
What safety context?Review the exact product warnings with the prescriberLabels[5]

The table is an original reading aid. It points to information in the published report, study protocol and product labeling; it is not a validated clinical scoring system. Leave an unanswered item marked as a question, and bring the original source to someone qualified to interpret it.

Keep a direct comparison separate from other trials

A head-to-head trial compares assigned treatments within the same study. Placing the headline from one trial beside a percentage from another study does not create that design. Before combining numbers, check whether the populations, treatment periods, regimens, outcome definitions and analysis rules match. Different questions can produce different estimates even when the ingredient names look familiar.

For SURMOUNT-5, the protocol distinguishes a modified treatment-regimen analysis from an efficacy analysis framed around continued treatment without other weight-management therapies. It also specifies methods for missing weight measurements. [2] You do not need to reproduce those models to make a useful note. Write down the analysis attached to the quoted number and ask for help if a chart or advertisement leaves it out. Avoid mixing estimates with different analysis rules as though they were one matched result.

Work through percentage points and relative percentages

The published report gives least-squares mean weight changes of −20.2% for tirzepatide and −13.7% for semaglutide at week 72. [1] For the arithmetic below, express those reductions as positive magnitudes: 20.2 and 13.7. These are group estimates from the studied regimens, not a prediction for a particular person.

Subtracting the reported reductions gives 20.2 − 13.7 = 6.5 percentage points. That is the gap between two percentages. Dividing that gap by the semaglutide estimate gives 6.5 ÷ 13.7 × 100 = about 47.4% greater relative reduction, using the rounded published inputs. Both calculations describe the same pair of estimates with different denominators. A relative headline does not mean an additional 47.4% of a participant’s starting body weight was lost.

In your notes, keep the two original percentages, the comparator used as the denominator and the measurement time together. Label the subtraction as percentage points and any division as relative percentage. Do not multiply either group estimate by your own weight to create a promised result or use this arithmetic as a medication dose ratio.

Match the study to the exact product question

Current Wegovy labeling includes tablets and an additional higher-dose injection option beyond the semaglutide regimens in this comparison. [4] SURMOUNT-5 did not test those options. Its result therefore should not be rewritten as a comparison of every current semaglutide formulation or regimen. Ask which exact product and intended use are relevant to the decision you are discussing.

Both Wegovy and Zepbound labeling contain important contraindications and warnings. [4] [5] A larger average weight reduction is one outcome; it does not establish that a medicine is the safest or most suitable option for every person. Bring your health history, other medicines and tolerability questions to the prescriber. This reading worksheet does not replace that product-specific review or supply a switching schedule.

Keep the product boundary when reading about compounded medicines as well. FDA explains that compounded drugs are not FDA-approved and are not reviewed by the agency for safety, effectiveness and quality before marketing. [6] The trial estimates do not establish the performance of a compounded formulation or a particular online care service.

Explore a disclosed research resource

SHARED OWNERSHIP

Weight Loss & Nutrition and Peptide Dossier share ownership.

Read Peptide Dossier’s comparison ↗

Peptide Dossier publishes a longer semaglutide–tirzepatide comparison with links to research and product information. Use it as additional editorial background, then follow the original source for the claim you want to discuss. The worksheet here remains usable with the study report and your own clinician.

Keep a private comparison note

Headline or claim I want to understand: __________
Original study link, identifier and publication date: __________
Population and important differences from my situation: __________
Exact products, route and studied regimens: __________
Outcome, time point and analysis named in the source: __________
Reported estimates, uncertainty and denominator: __________
Safety, tolerability or access questions for the clinician: __________
What this study leaves unanswered for my decision: __________

Keep this note privately; the page has no online health-data fields. Choose one clear question for the appointment, such as whether the studied product and population match the option being considered. Bring the source and leave missing information visible so the conversation can resolve it.

Sources & further reading

  1. Aronne and colleagues, SURMOUNT-5 Published Trial Abstract, 2025
  2. SURMOUNT-5 Public Study Protocol, Amendment c, 2023
  3. NIH NHLBI, How Clinical Trials Work
  4. Wegovy Current Prescribing Information
  5. Zepbound Current Prescribing Information
  6. FDA, Concerns with Unapproved GLP-1 Drugs

Sources checked November 19, 2026. Examples and worksheets are original illustrations unless stated otherwise.

Have a correction or a source we should consider?

Contact the publication ↗